Blood Coagulation Disorders, Inherited clinical trials
The registry lists 21 studies for Blood Coagulation Disorders, Inherited across more than 10 countries. 4 are recruiting or about to start. 1 of them are mainly about Blood Coagulation Disorders, Inherited (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 5 narrower conditions too, such as Hemophilia A: 1,125 studies, 187 open.
Get an email when these change. Save the Blood Coagulation Disorders, Inherited studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
BioMarin Pharmaceutical (8) · Spark Therapeutics, Inc. (3) · Genzyme, a Sanofi Company (2) · Assiut University (1) · University of Sao Paulo (1) · Hemab ApS (1) · Spur Therapeutics (1) · Sanofi (1)
What is being tested here
Drugs under test in Blood Coagulation Disorders, Inherited studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 2 Blood Coagulation Disorders, Inherited studies recruiting now, 0 (0%) set no upper age limit and 1 (50%) stop at 75 or younger. 2 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 21 studies, recruiting or not: 10% stop at 75 or younger and 5% at 65; 38% take children; 0% are for women only and 71% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered1
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaNov 13, 2026NCT07935356
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaRecruitingNCT07935356Phase 31 country
- Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut GovernorateNot yet recruitingNCT074101301 country
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitationNCT0576838612 countries
- Evaluation of Hemostasis in Bleeding and Thrombotic DisordersRecruitingNCT001785941 country
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/21 country
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanActive, not recruitingNCT066843141 country
- Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedNCT04684940Phase 1/27 countries
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive, not recruitingNCT06224907Phase 31 country
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedNCT04323098Phase 34 countries
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedNCT03520712Phase 1/24 countries
- Gene Therapy Study in Severe Haemophilia A Patients (270-201)CompletedNCT02576795Phase 1/21 country
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedNCT03370913Phase 313 countries
- A Gene Transfer Study for Hemophilia ACompletedNCT03003533Phase 1/25 countries
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsCompletedNCT03734588Phase 1/21 country
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedNCT03392974Phase 31 country
- Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A ParticipantsCompletedNCT038763014 countries
- AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)CompletedNCT0427255412 countries
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 317 countries
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 319 countries
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 32 countries
- Education Program for Patients Receiving Oral AnticoagulationStatus unknownNCT01339611Not applicable1 country